Of course, we say “yes!” Today at the Annual Meeting, our collaborators from the University of Texas MD Anderson Cancer Center (MDACC) and Sarah Cannon Research Institute at HealthOne, presented exciting new data demonstrating that matching patients to targeted therapies based on the unique molecular profile of the patient’s cancer leads to improved efficacy outcomes across a variety of key measures, including overall survival. Dr. Jennifer Wheler, Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at MDACC, presented these findings in a poster titled, “Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy” (abstract # 152886),
The data validate what we at Foundation Medicine already believe to be true. Importantly, these data illustrate the significant utility of integrating FoundationOne comprehensive genomic profiling into routine clinical practice and support the potential use of FoundationOne for patients with earlier-stage cancers in addition to advanced cancers. The patients in this study all had advanced cancer that progressed despite standard courses of treatment. 110 patients received genomic profiling with FoundationOne and were matched to a targeted therapy based on the molecular profile of their cancer. Improvements were seen across all efficacy measurements compared to 65 patients who received a non-matched therapy.
This is an incredible step forward for these patients who may have otherwise had very limited or no treatment options left to consider. Comprehensive genomic profiling is the path to making precision medicine a reality for cancer patients and we believe we are on the cusp of making it a critical part of routine cancer care.
For more information on the data, see our press release.